Prima BioMed - Stock Price History | IMMP
Historical daily share price chart and data for Prima BioMed since 2021 adjusted for splits. The latest closing stock price for Prima BioMed as of October 27, 2021 is 4.40.
- The all-time high Prima BioMed stock closing price was 24.00 on April 20, 2012.
- The Prima BioMed 52-week high stock price is 7.95, which is 80.7% above the current share price.
- The Prima BioMed 52-week low stock price is 1.65, which is 62.5% below the current share price.
- The average Prima BioMed stock price for the last 52 weeks is 3.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Prima BioMed Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2020 |
1.6798 |
1.8500 |
5.6900 |
0.6700 |
3.1400 |
75.42% |
| 2019 |
1.8493 |
2.0400 |
2.5700 |
1.2700 |
1.7900 |
-2.72% |
| 2018 |
2.3906 |
1.6400 |
3.9000 |
1.6400 |
1.8400 |
17.20% |
| 2017 |
2.1285 |
2.5300 |
2.9300 |
1.3200 |
1.5700 |
-32.91% |
| 2016 |
3.0369 |
3.9333 |
3.9333 |
2.1000 |
2.3400 |
-38.42% |
| 2015 |
3.8315 |
2.5000 |
19.7000 |
1.6337 |
3.8000 |
70.12% |
| 2014 |
3.6971 |
3.7033 |
5.6667 |
2.2337 |
2.2337 |
-39.08% |
| 2013 |
7.9732 |
12.3330 |
13.1667 |
2.8000 |
3.6667 |
-67.93% |
| 2012 |
14.8844 |
23.3333 |
24.0000 |
10.5000 |
11.4333 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.398B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
